AKUMS share price & delivery % — Akums Drugs and Pharmaceuticals

Filings & corporate actions

9 results filed

CSV

Next results · Q2 FY27

Expected 6 Nov 2026 – 25 Nov 2026

Estimate: filed 37–56 days after quarter end, last 8 times

Dividend

₹3.00 per share · last 3 Jul 2026

2026

8 AugresultsResults · Q1 FY27 · consolidated and standalone+4.7%NSE
18 JulshareholdingShareholding · 30 Jun 2026+1.7%NSE
3 JuldividendDividend · ₹3.00 per share-1.7%
14 MayresultsResults · Q4 FY26 · consolidated and standalone-2.1%NSE
7 AprshareholdingShareholding · 31 Mar 2026-0.8%NSE
13 FebresultsResults · Q3 FY26 · consolidated and standalone+5.7%NSE
12 JanshareholdingShareholding · 31 Dec 2025-0.1%NSE

Reaction to results · all yearsrose on day 0 in 2 of 9 CSV

Quarter	Filed	Day 0	+5D	+20D	Rel vol
Q1 FY27	8 Aug 2026	+4.7%	+6.7%	+8.2%	9.5×
Q4 FY26	14 May 2026	-2.1%	-1.5%	+17.4%	1.8×
Q3 FY26	13 Feb 2026	+5.7%	+5.1%	+2.8%	25.1×
Q2 FY26	13 Nov 2025	-3.0%	-3.6%	-3.3%	6.1×
Q1 FY26	8 Aug 2025	-0.1%	-0.2%	-2.4%	3.3×
Q4 FY25	26 May 2025	-0.8%	-3.3%	-7.9%	7.4×
Q3 FY25	6 Feb 2025	-2.4%	-8.9%	-14.3%	0.9×
Q2 FY25	9 Nov 2024	-10.0%	-27.1%	-23.0%	2.8×
Q1 FY25	24 Aug 2024	-5.0%	-11.4%	-9.0%	—
Average		-1.4%	-4.9%	-3.5%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV

Revenue YoY+13.9%

Profit YoY+56.1%

Interest cost YoY+114.0%

Revenue QoQ+0.8%

Profit QoQ+24.1%

CAGR	2Y	3Y	4Y	5Y	6Y	7Y
Revenue	—	—	—	—	—	—
Profit	—	—	—	—	—	—

Key data

CSV

Open802.00

Day range796.30 – 818.00

52-week range409.30 – 838.80

From 52w high-2.9%

RSI (14)59.2

ATR (14)26.75

Volume1.28L

Avg volume (20D)2.72L

Rel volume0.47×

Volatility (1Y)32.8%

Turnover₹10.5Cr

SMA 50 / 200753.01 / 577.87

Delivery percentage

Latest · 6 Oct 202655.9%

20-day avg51.5%

1-year avg51.6%

Percentile (own history)65th

Range13.6–100.0%

Sessions538

Over the last 20 sessions AKUMS settled 51.5% of its traded quantity, which is above average for an NSE equity. That is in line with its own one-year average of 51.6%. The latest session ranks higher than 65% of the 538 sessions on record for it.

What delivery percentage measures Scan the whole market on delivery

IndustryPharmaceuticals

PeersDIVISLAB LAURUSLABS SUNPHARMA WOCKPHARMA DRREDDY MOREPENLAB

Performance returns

CSV

	1D	1W	1M	3M	6M	1Y
Price	+1.66%	+1.84%	+4.37%	+25.36%	+63.24%	+82.39%

Valuation

CSV

Market cap₹12,822 Cr

P/E (TTM)43.8

EPS (TTM)18.60

Shares outstanding15.31Cr

Listed6 Aug 2024

Ownership

CSV

Promoter75.26%

Promoter Δ QoQ0.00 pp

Public22.01%

FII1.91%

DII13.44%

Pledged0.00%

Quarterly results · consolidated

CSV

	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue (₹ Cr)	1,017.5	1,159.6	1,157.9	1,166.6
YoY chg	-1.5%	+14.8%	+9.7%	+13.9%
Net profit (₹ Cr)	42.7	67.7	81.3	101.0
YoY chg	-35.9%	+2.1%	-45.6%	+56.1%
Net margin	4.2%	5.8%	7.0%	8.7%
EPS	2.66	4.33	5.53	6.53

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 75.26% · public 22.01%

2024-082026-06

Promoter
Public and others

Promoter: 75.26%
Public: 22.01%
Promoter change: 0.00 pp
Filed: 18 Jul 2026

FII: 1.91%
DII: 13.44%
Promoter pledged: 0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV

₹ crore, as filed

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue from operations	1,019.1	1,033.1	1,010.4	1,055.5	1,024.0	1,017.5	1,159.6	1,157.9	1,166.6
Other income	6.5	13.5	14.6	17.5	26.7	32.4	34.3	35.3	30.4
Total income	1,025.7	1,046.6	1,025.0	1,073.1	1,050.8	1,049.9	1,193.9	1,193.2	1,197.0
Total expenses	938.2	958.7	938.7	1,006.2	955.1	984.2	1,076.1	1,070.2	1,057.8
└ Finance costs	13.0	11.9	5.1	4.5	23.1	23.3	23.7	23.9	24.8
└ Depreciation	34.1	34.9	44.5	40.0	36.9	37.9	39.6	40.1	41.1
Profit before tax	87.5	91.6	91.1	75.1	95.6	65.7	99.6	121.2	139.2
Tax expense	26.3	24.9	24.7	(74.5)	31.0	23.0	31.9	39.9	38.3
Net profit	61.2	66.7	66.3	149.6	64.7	42.7	67.7	81.3	101.0
EPS	4.21	4.37	4.26	9.64	4.15	2.66	4.33	5.53	6.53
Net margin	6.01%	6.45%	6.56%	14.17%	6.32%	4.20%	5.84%	7.03%	8.66%
PBT margin	8.58%	8.87%	9.01%	7.12%	9.34%	6.45%	8.59%	10.47%	11.93%
Tax rate	30.03%	27.23%	27.17%	-99.11%	32.37%	34.99%	32.03%	32.89%	27.48%

^A audited · ^R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 8 Aug 2026.

AKUMS at a glance

AKUMS closed at ₹814.65 on 6 Oct 2026, +1.66% on the day, +82.4% over one year, 2.9% below its 52-week high of ₹838.8.
Delivery was 55.9% of traded quantity on 6 Oct 2026, the 65th percentile of its own 538 sessions with a reading (20-session average 51.5%, 1-year average 51.6%).
Market capitalisation is ₹12,822 crore at a trailing P/E of 43.8 (trailing EPS ₹18.6).
Q1 FY27 results (consolidated, filed 8 Aug 2026): revenue ₹1,167 crore (+13.9% year on year), net profit ₹101 crore (+56.1%); the price moved +4.7% on the first session after.
Promoters held 75.26% at 30 Jun 2026, unchanged on the previous filing.
Q2 FY27 results are expected between 6 Nov 2026 and 25 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV

Macro sectorHealthcare

Basic industryPharmaceuticals

ISININE09XN01023

SeriesEQ

Listed6 Aug 2024

History from6 Aug 2024

Sessions538

Turnover rank#753

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSE All Healthcare stocks on the NSE